Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Accounts Payables: 2023-2025

Historic Accounts Payables for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $3.5 million.

  • BioLineRx's Accounts Payables fell 44.70% to $3.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $3.5 million, marking a year-over-year decrease of 44.70%. This contributed to the annual value of $5.6 million for FY2024, which is 48.63% down from last year.
  • Latest data reveals that BioLineRx reported Accounts Payables of $3.5 million as of Q2 2025, which was down 26.17% from $4.7 million recorded in Q1 2025.
  • BioLineRx's 5-year Accounts Payables high stood at $10.9 million for Q4 2023, and its period low was $3.5 million during Q2 2025.
  • Moreover, its 3-year median value for Accounts Payables was $6.5 million (2023), whereas its average is $6.6 million.
  • Examining YoY changes over the last 5 years, BioLineRx's Accounts Payables showed a top increase of 15.70% in 2024 and a maximum decrease of 48.63% in 2024.
  • BioLineRx's Accounts Payables (Quarterly) stood at $10.9 million in 2023, then tumbled by 48.63% to $5.6 million in 2024, then plummeted by 44.70% to $3.5 million in 2025.
  • Its Accounts Payables was $3.5 million in Q2 2025, compared to $4.7 million in Q1 2025 and $5.6 million in Q4 2024.